Company: MDCXW
Filing Date: 2025-09-11
Form Type: DRS
Source: 0001062993-25-015568
Chunk: 150

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-11
Form: DRS
Chunk 150
---
 to day 155, with a probability greater than 90%.

In November 2024, the FDA approved a Phase 2b study of Teverelix to treat AUR. The planned Phase 2b study is a randomized controlled double-blind study involving 390 men after a successful trial without catheterization in 60 to 70 sites in the United States and European Union. The patients will receive either a single intramuscular or a single subcutaneous injection (90 mg or 120 mg) or placebo in addition to standard therapy. The primary endpoint for the Phase 2b study is a composite of AUR, need for surgery or poor urinary flow metrics in the first 28 weeks plus 24 weeks follow up.

Patent Protection

Composition of matter patents for Teverelix have a natural expiration in 2039 and pending method of use patent applications, if issued, will have a natural expiration between 2044 and 2045, subject to any patent term adjustment that may be awarded. The table below summarizes the patents we hold for Teverelix, each of which is a utility patent.

| Country       
 Name          | Title                                                          | Application 
         No. | Priority  
 Date      | Filed      
 Date       |     Patent 
        No. | Issue     
 Date      | Projected  
 Expiration 
 Date       | Status  | Assignee  
 (s)       |
| United States | Composition for treating one or more estrogen related diseases |  17/050,430 | 4/26/2018 | 10/23/2020 | 11,446,351 | 8/31/2022 | 4/25/2039  | Issued  | LifeArc   |
| China         | Composition for treating one or more estrogen related diseases |   112041028 | 4/26/2018 | 4/25/2019  |            |           | 4/25/2039  | Pending | Life Agco |
| Israel        | Composition for treating one or more estrogen related diseases |      277876 | 4/26/2018 | 4/25/2019  |            |           | 4/25/2039  | Pending | LifeArc   |
| Japan         | Composition for treating one or more estrogen related diseases |  2021522227 | 4/26/2018 | 4/25/2019  |            |           | 4/25/203